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Abstract
The study of tumourigenesis commonly involves the use of established cell lines or single cell suspensions of primary
tumours. Standard methods for the generation of short-term tumour cell cultures include the disintegration of tissue based
on enzymatic and mechanical stress. Here, we describe a simple and rapid method for the preparation of single cells from
primary carcinomas, which is independent of enzymatic treatment and feeder cells. Tumour biopsies are processed to
1 mm3 cubes termed explants, which are cultured 1–3 days on agarose-coated well plates in specified medium. Through
incisions generated in the explants, single cells are retrieved and collected from the culture supernatant and can be used for
further analysis including in vitro and in vivo studies. Collected cells retain tumour-forming capacity in xenotransplantation
assays, mimic the phenotype of the primary tumour, and facilitate the generation of cell lines.
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Introduction
Nowadays, the great majority of knowledge related to tumour
biology stems from or was verified in established tumour cell lines,
which have at times been generated long ago and have been
passaged innumerable times. Additionally, concepts in molecular
oncology are addressed in vivo using sophisticated animal models of
disease, e.g. transgenic and knockout mouse strains [1]. However,
the use of animal models is time consuming and still requires
verification of the unravelled phenotype in independent cell
systems. Genetic and phenotypic changes, occurring in culture
during selection for cells able to adapt to in vitro conditions, might
impact on the expression and functionality of genes of interest and
therefore potentially bias studies. Especially for the case of
genomic analyses, divergences between primary cells and perma-
nent lines might be of great importance and are controversially
discussed [2]. This is even more pronounced in the case of
tumours with phenotypically and molecularly heterogeneous sub-
types, such as for example breast cancer. Here, tumour cell lines
revealed genetically more complex than primary tumours, which
renders the choice of representative cell lines imperative [3].
Hence, cell lines and primary cells have their advantages and
disadvantages, which eventually complement each other. Cell lines
represent a rather pure source of tumour cells, which might have
acquired additional, cell culture specific modifications and/or lost
primary cell-specific features. Primary tumour cells obviously
reflect the in vivo situation in the human being more closely, but
might contain contaminating non-tumour cells and are commonly
more difficult to obtain in sufficient amounts. Hence, the
comparison of primary cultures and long-term established cell
lines is a matter of research, which however cannot be conducted
in every given case. Nonetheless, the study of primary tumour cells
is of utmost importance to obtain insights in molecular processes
occurring in situ as closely as possible.
Commonly, the generation of short-term primary cultures is
accompanied by enzymatic and/or mechanical treatment of cells
[4]. Treatments with trypsin, collagenases, and DNAses follow the
mechanical disruption of tissue integrity to release tumour cells
from the extracellular matrix [5]. Alternatively, more complex
methodologies such as centrifugation on Percoll gradients or
micro-dissection of the cells of interest are in use [6]. We have
concentrated on the isolation of primary tumour cells from
surgical specimens of head and neck carcinomas without
implementating a step of enzymatic digestion. The method relies
on the incision of small explants from primary biopsies and the
culture in supplemented Airway Epithelial Cell Growth medium,
which is optimised for primary cells [7,8]. Tumour cells were
reproducibly retrieved in the culture medium within one to three
days, and could be used for in vitro testing and re-implantation into
immunocompromised mice. In vivo, single cells reconstituted
tumours, which perfectly mimicked the human tumours of origin.
In addition, cell lines, which express classical markers of
carcinoma cell lines can be generated from explanted cells upon
serial dilutions.
In summary, we present a rapid method to retrieve single
tumour cells from primary carcinoma specimens without enzy-
matic treatment.
Materials and Methods
Generation of explants
Fresh primary specimens of head and neck carcinomas (n = 28)
with a minimal size of 5 mm3 were processed within 30 min after
surgical removal. Size refers to biopsies macroscopically devoid of
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fat tissue, musculature or any other surrounding, non-tumour
tissue. All biopsies were obtained in accordance with the local
ethics committee of the Ludwig-Maximilians-University (#426-11)
and exclusively with written informed consent of each patient after
education by surgeons in charge. Specimens were cut into 1 mm3
cube-like pieces using sterile Feather disposable scalpels Nu11.
These 1 mm3 cube-like pieces are referred to as explants. A total
of three to five incisions were made with the point of the scalpel on
the sides of the explants to generate small channels ranging
crosswise through the explants. These incisions loosen the tissue
structure and generate channels, which facilitate the exit of cells
from explants. Explants and incisions were performed in a drop of
NaCl solution (0.9% m/V) to avoid drying of explants. Maximally
five explants were placed in one well of 24-well format plates or
one explant per well in 96-well format plates. To do so, explants
were harvested with 1 ml pipette tips and transferred into culture
plate wells. Before usage the pipette tips were trimmed with a
scalpel in order to enlarge the tip hole. Culture plates were coated
beforehand with a 2% agarose (Biozym, ME Agarose, Hess.
Oldendorf, Germany) solution in PBS with a 0.05% matrigel coat
(Growth Factor Reduced BD Matrigel Matrix BD Biosciences,
USA). 300 ml of agarose solution were used for a complete
coverage of wells in 24-well format plates. Ice-cold matrigel was
resuspended in ice-cold PBS to a final concentration of 0.05%,
mixed vigorously, and was added as a thin layer (50 ml). Coated
plates were stored at 4uC before use. In case of the generation of
permanent cell lines, only 250 ml of agarose solution were used to
keep a crescent-like area in the well, which was free of agarose and
can serve as an adhesion platform for cells in the absence of
matrigel. Explants were cultured in Airway Epithelial Cell Growth
medium supplemented with SupplementMix C39165 (Promocell,
Heidelberg, Germany) for one to seven days. The combination of
small-sized explants, incisions, and specified cell culture medium
containing chemoattractants warranted an efficient migration of
cells out of explants into the supernatant. Cells were collected
between days 1 to 3 based on microscopic control of the cell
culture supernatants’ content and subjected to further in vitro or in
vivo analyses. Collection of cells was conducted upon resuspension
and harvesting of the complete supernatant with 100 ml pipette
tips in order to strictly avoid harvesting explants and to harvest all
cells in suspension. Thereafter, cells were gently centrifuged at 0.3
relative centrifugal force (RCF) for 2 minutes and pellets were
Table 1. Primary carcinomas used for the generation of explants.
Tumour IHC EpCAM EpCAM MFI-R d1 EpCAM MFI-R d2–5 Mean MFI-R
tonsillar +++ 8.3 4.7 6.5
soft palate +++ n.d. 4.8 4.8
floor of the mouth +++ n.d. 7.5 7.5
oropharynx +++ 6.3 16.2 11.25
oropharynx +++ 4.4 2 3.2
CUP +++ 4.2 4.2 4.2
larynx +++ 6.5 5.7 12.2
tonsillar +++ 4 2.9 3.45
tonsillar +++ 4.2 0.3 2.25
hypopharynx +++ 4.9 n.d. 4.9
hypopharynx +++ 22.4 n.d. 22.4
tonsillar +++ 0.8 n.d. 0.8
tonsillar ++ 17.5 2.3 9.9
tonsillar ++ 2.3 2.1 2.2
oropharynx ++ 1.5 5.5 3.5
oropharynx ++ n.d. 1.7 1.7
oropharynx ++ 0.8 1.3 1.05
soft palate ++ 1.8 1 1.4
larynx ++ n.d. 0.7 0.7
hypopharynx ++ n.d. 1.4 1.4
base of tongue ++ 2.7 3 2.85
oropharynx ++ 2.1 0.8 1.45
larynx 2/+ 3.4 n.d. 3.4
larynx 2 n.d. 1.3 1.3
oropharynx + 0.9 1.6 1.25
tongue + 1.2 1.1 1.15
oropharynx + 1.5 1.5 1.5
larynx + 1.1 1.6 1.35
The indicated primary carcinomas were processed to explants and collected cells were analysed for the expression of EpCAM upon immunohistochemistry (IHC) and
flow cytometry with EpCAM-specific antibodies. MFI-R: mean fluorescence intensity ratio (EpCAM/isotype control antibody). Staining intensities represent +++: strong;
++: intermediate; +: weak; 2: negative. n.d.: not determined.
doi:10.1371/journal.pone.0055540.t001
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resuspended in PBS or cell culture medium, depending on further
treatment.
Generation of cell lines
To establish permanent cell lines, explants were plated on
incompletely agarose-coated wells (see above). Cells, which had
migrated out of explants, were allowed to adhere to uncoated
areas for 5–7 days. Thereafter, adherent cells were detached from
the culture well upon trypsin treatment with a 10 ml pipette tip and
were transferred onto standard culture plates (Nunc, Langensel-
bold, Germany). Serial dilutions ranging from 1:10–1:1000 were
prepared to eliminate fibroblasts contamination.
Flow cytometry
Before flow cytometry measurement, cells were washed three
times in FACS buffer (PBS containing 3% FCS). Cells were
incubated with the EpCAM specific antibody Ber-Ep4 (Dako,
Hamburg, Germany; 1:50 in FACS buffer, 15 min). After
centrifugation, supernatant was discarded and cells incubated
with a fluorescein isothiocyanate (FITC)-conjugated secondary
antibody (1:50 in FACS buffer, 15 min). Cells were again spun
and resuspended in PBS containing 3% FCS+1 ml PI (propidium
iodide, 1 mg/ml). Cell surface expression of EpCAM was analysed
in a FACS Calibur cytometer (Becton Dickinson, Heidelberg,
Germany). Control staining was performed using a mouse IgG1
isotype control antibody (Dako, Hamburg, Germany). Immuno-
characterisation of one established cell line referred to as PiCa was
performed with the following antibodies: CD11a, CD11c, CD14,
CD16, CD28, CD40-L, CD45-RA, CD56, EGF-R, EpCAM/Ber-
Ep4, ICAM-1, IL2-R, integrin a4b1, VCAM-1 (all Dako,
Hamburg Germany), CCR5 (R&D Systems, Minneapolis, USA),
CD133 (Miltenyi, Bergisch Gladbach, Germany), CD20, N-
cadherin (both Sigma Aldrich, Taufkirchen, Germany), CD44
(Dianova-Immunotech, Hamburg, Germany), CD90 (DCS, Ha
mburg, Germany), CD95/Fas, Fas-L (both BD Pharmingen,
Heidelberg, Germany), E-cadherin (Cell Signaling), integrin b3,
SSEA-1, VEGF (all Santa Cruz, Heidelberg, Germany), MHC
class 1 (Epitomics, Burlingame, USA), MHC class 2 (Oncogene
Science, Wilex AG, Munich Germany), Mucin 1 (Novo Castra,
Wetzlar, Germany).
Immunocytochemistry and immunohistochemistry
Immunocytochemistry and immunohistochemistry were per-
formed as described [9] using the EpCAM-specific antibody Ber-
Ep4 and the Ki-67-specific clone Ki-67 antibody (both Dako,
Hamburg, Germany).
Transient transfection, plasmids, siRNAs
PiCa cells were transiently transfected using MATra (Iba,
Goettingen, Germany) or Fugene (Promega, Mannheim, Ger-
many) reagents according to the manufacturers’ protocol. The
peGFP-C1 expression plasmid from Clontech (Mountain View,
USA) was used for transient transfections. The following siRNA
oligonucleotides were used for the transient knock-down of
EpCAM in PiCa cells:
N EpCAM-specific siRNA: (59-UGCCAGUGUACUUCA-
GUUG-39),
N control siRNA: (59-UCGUCCGUAUCAUUUCAAU-39).
Xenotransplantation in immunocompromised mice
All experiments were performed with the approval of the Ethics
Commission of the Ludwig’s Maximilian University Munich
(Az.55.2-1-54-2532-101-07). Primary cells or PiCa cells (16104–
56106 cells per injection in 100 ml medium and 100 ml Growth
Factor Reduced BD Matrigel Matrix BD Biosciences, California,
USA) were injected in the flanks of 6–8 week old NOD/SCID
mice. After tumour development (latest 28 days after injection),
mice were sacrificed by isofluran inhalation, tumour weight was
assessed using a precision weighting scale and tumour tissues were
frozen for immunohistochemical analyses.
Results
Short-term explantation of tumour cells from primary
head and neck carcinoma specimens
Primary tumour specimens from various localisations of the
head and neck area (Table 1) were subjected to a rapid
explantation method with the aim to retrieve single tumour cells.
Biopsies were first cut into approximately 1 mm3-sized cubes
(termed explants) into which three to five incisions were made.
These explants were then transferred onto agarose-coated 96- or
24-well plates and cultured in supplemented Airway Epithelial Cell
Growth medium. Supernatants of each well were collected after
one to three days. To compare explants with matched primary
tumours, a sample of each tumour was cryo-preserved at the
beginning of the procedure. Cells present in supernatants were
used for cytospin and flow cytometry-assisted stainings, in vitro and
in vivo studies, and eventually to establish permanent cell lines
(schematic representation in Figure 1). Tumour biopsies had to be
at least 5 mm3 in size to retrieve sufficient tumour cells for further
analysis. This size refers to biopsies macroscopically devoid of fat
tissue, musculature or any other surrounding, non-tumour tissue.
Figure 2A exemplifies the generation of explants from a tongue
carcinoma biopsy into 24-well format culture plates. Within one
day, cells migrated out of the explant and remained at first in the
culture supernatant without adhesion owing to agarose coating
(Figure 2B and Figure S1A). Staining of cryo-preserved explant
samples show a staining for the pan-epithelial marker EpCAM and
rare or no staining for the pentaspan cell surface protein CD133
(Figure 2C, upper panels). In these explants, enzyme-independent
dissociation and loss of structure were seen over the time course of
three days (Figure S1B). Cells that had migrated out of the explant
into the supernatant were collected and subjected to immuno-
staining of cytospins on glass slides. Single cells expressed EpCAM
in the majority of cells, while the cancer stem cell marker CD133
was restricted to rare single cells (Figure 2C, lower panels). Further
immunocytochemical analyses revealed that .80% of cells in the
supernatants of explants were positive for the epithelial marker
pan-cytokeratin, whilst negative for the fibroblast marker 5B5
(Figure S1C).
Out of 28 specimens, EpCAM staining upon immunohisto-
chemistry (IHC) of primary tumour biopsies varied: 12 carcinomas
showed positive staining for EpCAM in immunohistochemistry
(IHC) stainings of the primary tumours, while 10 carcinomas
expressed intermediate levels and 6 carcinomas expressed low
levels or no EpCAM (Table 1). Single cells from explants of these
specimens were assessed for the expression of EpCAM upon
FACS analysis at day 1 and between day 2 to 5. Except for one
tonsillar, one oropharynx, and one soft palate carcinoma, which
did not allow explantation of EpCAM-positive single cells,
EpCAM-positive single cells could be retrieved from all primary
specimens expressing EpCAM to strong or intermediate levels
(Table 1). Specimens showing a low or negative expression level of
EpCAM in IHC, yielded single cells matched expression levels
(Table 1). Numbers of vital cells retrieved from explants were
assessed systematically at day 1–2 in six specimens and ranged
Tumour Explants
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from 6.46102 to 56105 per 1 mm3. The vitality of cells ranged
from 17% to 81% and the expression of CD133 between 0% and
0.6%. In case of longer cultivation of explants, the numbers of cells
retrieved in the supernatant decreased, however the vitality of cells
increased up to 100%.
Single cells from short-term explants are tumourigenic in
vivo
In an attempt to further characterise the tumourigenic potential
of single cells from explants, we have processed a biopsy of a
hypopharynx carcinoma to explantation. Primary carcinoma cells
strongly expressed EpCAM especially at the tumour leading edges,
which correlated with areas of proliferation as monitored upon Ki-
67 staining (Figure 2D). This correlation of EpCAM and Ki67
staining confirmed earlier findings related to the regulation of
proliferation and expression of Cyclin D1 by EpCAM [10].
Although being of squamous nature, this hypopharynx carcinoma
grew in an adenocystic manner forming lobules and gland-like
structures (Figure 2D). Cytospins of single cells showed a specific
expression of EpCAM in approximately 70–80% (Figure 2E),
Figure 1. Schematic representation of the method of tumour explant formation. Specimens of primary carcinomas (.5 mm3) are cut into
approximately 1 mm3 cube-like structures termed explants. One part of the primary carcinoma is cryo-preserved as a matched control for explanted
cells. Incisions are generated in explants, which are then transferred into agarose-coated 96- or 24-well plates for a time period of 1–3 days.
Supernatants are collected and cells harvested upon centrifugation for subsequent analysis or examination.
doi:10.1371/journal.pone.0055540.g001
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which was confirmed upon FACS staining (86%, Figure 2F). A
single cell suspension of 1–56106 cells was injected subcutaneously
into the flank of immunocompromised NOD-SCID mice (n = 2) in
a 1:1 dilution in matrigel. Tumour formation was assessed upon
palpation on a daily basis. Within 28 days, xenotransplanted single
cells generated tumours with a morphology and EpCAM
expression pattern similar to the human carcinoma of origin.
Xenotransplants grew in a focal, gland-like manner and expressed
EpCAM and Ki-67 in a correlated manner at the edges of tumour
areas (Figure 2G). Comparably to the primary specimen, EpCAM
expression was strongest in areas of strong proliferative activity as
monitored upon the expression of Ki-67 (Figure 2G, middle and
lower panels).
Single cells from short-term explants allow for the
establishment of permanent cell cultures in vitro
Next, single cells were retrieved from larynx carcinoma biopsy,
which displayed an intermediate to strong expression of EpCAM
in approximately 95–100% of cells (Figure 3A, upper left panel).
This expression pattern of EpCAM was similarly observed in
explanted single cells in culture supernatant (Figure 3A, lower left
panel). Fibroblasts migrating out of explants were observed after
7–14 days, hence single cells , which had adhered to the spared
agarose-free area, were harvested at day 7. Serial dilutions in 24-
well format were performed in order deplete remaining fibroblasts.
The resulting cell line termed PiCa permanently grew in culture in
supplemented Airway Epithelial Cell Growth medium. In order to
adapt PiCa cells, serial diluation of Airway Epithelial Cell Growth
medium with HAM’s F12/M199 medium and 10% fetal calf
serum was used on a weekly basis to achieve a full replacement of
Airway Epithelial Cell Growth medium. PiCa cells cultured in
monolayers displayed primarily cells characterised by an epithelial,
cobblestone-like phenotype, interspersed with bigger and more
flattened cells regularly observed in permanent cultures of head
and neck carcinomas such as FaDu and PCI cells (Figure 3A, right
panel). The expression of various cell surface markers associated
with different cell lineages was assessed on PiCa cells upon FACS
analysis with specific antibodies. PiCa cells strongly expressed
markers of epithelial cells including EpCAM, EGF-R, CD44
(Figure 3B), ICAM-1, and Mucin-1 (Table 2), along with more
ubiquitous markers such as CD95 (Fas) and MHC class 1 (Table 2).
PiCa cells did not express markers of immune cells (CD20, CD28,
CD40-L, CD45RA, CD56, CD90, IL2-R), nor of macrophages/
monocytes (CCR5, CD11a, CD11c, CD14, CD16) (see Table 2
for detailed immune reactivity).
Next, we tested the feasibility of PiCa cells to be extrinsically
modulated with respect to the expression of endogenous proteins.
PiCa cells were transiently transfected with small inhibitory RNA
molecules (siRNAs) specific for the tumour-associated antigen
EpCAM or with control siRNAs. After 24 h, the expression levels
of EpCAM were addressed upon FACS analysis. Transient
transfection of EpCAM-specific siRNA resulted in a maximal
knock-down efficiency of 72% of EpCAM protein expression at
the cell surface (Figure 3C). The efficiency of a transient transfer of
expression plasmids into PiCa cells was monitored with a plasmid
encoding the green fluorescence protein GFP and using two
different transfection methods, i.e. MATra and lipofection. After
24 h, nearly 50% of PiCa cells expressing GFP were detected upon
FACS measurement (Figure 3D).
The tumourigenicity of PiCa cells was assessed in vivo in
immunocompromised NOD-SCID mice in a pilot experiment.
Three concentrations of PiCa cells (16104, 16105, 16106 cells per
injection) were subcutaneously injected into both flanks of NOD-
SCID mice (n = 1 for each cell concentration). Tumour formation
was assessed upon daily palpation and tumour weight measured
after surgical excision of tumours at day 21. Similarly to the
primary specimen of origin, PiCa cells established carcinomas
characterised by a focal growth and a strong expression of
EpCAM at the edges of tumour areas (Figure 3E). Each of the
chosen PiCa cell concentrations generated tumours in vivo with
weights ranging from 13 to 23 mg (Figure 3E, lower table). Thus,
PiCa cells retained a tumour phenotype similar to the specimen of
origin.
Discussion
Functional analyses of molecules involved in processes of cancer
comprises three types of experimental systems: animal models of
cancer [11], primary short-term cultures of tumour cells ex situ, and
permanent cancer cell lines [12]. Each system displays advantages
and disadvantages, which are inherent to the methods used.
Knowledge about the actual situation in patients is a prerequisite
to fully understand underlying mechanisms of tumourigenesis and,
eventually, to set up efficient therapeutic modalities such as
chemotherapy and adjuvant immunotherapy. Primary cancer cells
from patients analysed ex situ represent closest the in vivo situation,
but require a rapid method for the isolation of cancer cells owing
to the short-term culture opportunities and the associated necessity
for repeated experiments. Conventional methods to isolate
primary tumour cells from human biopsies rely on enzymatic
disaggregation and mechanical mincing [4,13]. Although func-
tional, enzymatic treatment may not only degrade the extracellular
matrix (ECM) and DNA, but might also affect tumour cells
themselves, e.g. via the partial degradation of trypsin-sensitive
substrates. Isolation of lymphocytic cells from the liver with or
without treatment with collagenase yielded different cell types
Figure 2. Single cells from head and neck specimens recapitulate primary tumours. (A) Biopsy of a hypopharynx carcinoma was processed
to explants of approx. 1 mm3 and transferred into agarose-coated 24-well plates. Shown is the primary tumour biopsy and explants in wells. (B) Upon
incision and cultivation in specified medium, cells migrate out of the explant and settle in the well. Shown is one representative example at day one.
(C) Upper panels: Explants were collected after one day, cryo-preserved and processed to sequential sections before staining with EpCAM-, CD133-
specific or an isotype control antibody as indicated. The structure of explants begins to disintegrate and cells migrate away from the major tumour
area and are released into the supernatant. Cells express EpCAM but no CD133. Lower panels: Single cells migrating out of explants were subjected to
an EpCAM-, CD133 or isotype control antibody staining. The majority of cells expressed EpCAM and only rarely expressed CD133. (D) Matched
primary carcinoma was stained for the expression of EpCAM and Ki-67. Shown are 406 (upper panel) and 2006magnifications (middle and lower
panels) of the indicated stainings. (E) Single cells from explants of primary specimen shown in (D) were stained in cytospins with EpCAM-specific
(upper panel) or an isotype control antibody (lower panel). (F) Cell surface expression of EpCAM on single cells from explants of primary specimen
shown in (D) was analysed upon flow cytometry with specific antibodies. Left dot plot represents isotype control, while right dot plot represents
EpCAM staining. Dot plot statistics according to the marker set for both graphs are given for isotype control and EpCAM staining. (G) Single cells (1–
56106) from explants of primary specimen shown in (D) were xenotransplanted subcutaneously in immunocompromised NOD-SCID mice. After 28
days tumours were surgically removed, cryo-preserved, and stained for the expression of EpCAM and Ki-67. Shown are 1006(upper panel) and 2006
magnifications (middle and lower panels) of the indicated stainings.
doi:10.1371/journal.pone.0055540.g002
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[14], pointing towards an influence of enzymatic treatment on the
capacity of cells to emigrate from tissues. Accordingly, it was
advised to adapt the time of exposure to ECM-degrading enzymes
for each tumour type in order to achieve a partial enzymatic
degradation [13].
Therefore, we have developed an alternative method to isolate
tumour cells from primary cancer biopsies without a need for
enzymatic treatment. To facilitate the dissociation and emigration
of tumour cells from the explant into the cell culture medium, we
chose small sizes of explants (1 mm3), generated incisions in these
explants, which provide channels for cells to exit explants, and
cultivated explants in supplemented Airway Epithelial Cell
Growth medium, which is adapted for primary cells [7,8,15].
Cryosections of explants at various time points indicated a
progressive disintegration of these structures and a relief of
EpCAM-positive cells from the bulk. Although the precise
molecular mechanism of disintegration of extracellular matrix by
cells emigrating from explants is unknown, the contribution of
membrane-associated proteases such as matrix metalloproteinases
is to be expected [16]. The great majority of cells emigrating from
explants expressed the signalling active membrane protein
EpCAM, which is an activator of MMP7 and might thereby
contribute to single cell emigration [17]. This is corroborated by
stainings of cryo-preserved explants at succeeding time points,
Figure 3. Generation of a permanent cell line from tumour explants. (A) Matched sample (upper left panel) and single cells (lower left panel)
obtained from explants of a larynx carcinoma were stained for the expression of EpCAM. Harvested cells were passaged to establish a permanently
growing cell line. PiCa cells grew in adherent manner and displayed heterogeneity in morphology (right panel). (B) PiCa cells were monitored for the
cell surface expression of EpCAM, EGF-R, and CD44 using specific antibodies. Cells represented one determined population (FSC) and were vital (PI) as
shown in the dot plot graph (upper left). (C) PiCa cells were transiently transfected with control or EpCAM-specific siRNA. After 24 hrs, cells were
analysed for the cell surface expression of EpCAM upon flow cytometry. Isotype control staining is depicted as solid, purple curve, control siRNA as
green line, and EpCAM-siRNA as dashed pink line. (D) PiCa cells were transiently transfected with the eGFP-C1 expression plasmid. After 24 hrs,
expression of GFP was assessed upon flow cytometry. Dot plots graphs represent control transfectants (upper panel) and GFP transfectants (lower
panel). Quadrants were set according to control transfectants and statistics are given below. (E) PiCa cells (16104, 16105, 16106) were
subcutaneously injected into the left and right flanks of immunocompromised NOD-SCID mice. After 21 days, tumours were surgically removed, cryo-
preserved and stained for the expression of EpCAM. Matched primary specimens were stained in parallel (left panels) to xenotransplants (right
panels) and are depicted in 1006and 2006magnification. Injected cell numbers and tumour weights with mean and standard deviations are given
in tabular manner.
doi:10.1371/journal.pone.0055540.g003
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which demonstrated an ongoing loosening of tissue structures
mostly around EpCAM-expressing cells. Furthermore, microscop-
ic observation of explants in vitro disclosed a preferential
emigration of cells at distinct sites, supposedly representing the
incisions previously generated (Figure S1).
Cells, which migrated out of the explant were mostly vital,
sufficient in numbers for subsequent in vitro and in vivo studies, and
expressed markers of epithelial origin (EpCAM, cytokeratins) but
not fibroblast (5B5). The tumourigenic capacity of single cells that
had migrated out of explants was confirmed in vivo upon
xenotransplantation into immunocompromised mice. Importantly,
short-term isolates of tumour cells recapitulated the phenotype of
matched cryo-preserved samples, thus suggesting that they closely
resemble the primary tumours of origin and pheno-copy them
upon xenotransplantation. The short time between biopsy
procedure, single cell retrieval, and subsequent analysis in vitro
and in vivo does not allow for ample genetic alterations. This might
particularly add to the stability of phenotype and the reliability of
the method. Moreover, a hallmark of the presented method is the
lack of enzymatic treatment of cells, which contributes to preserve
the surface integrity and antigen expression pattern of tumour
cells. Obviously, this method will to a certain degree lead to a
preferential isolation of cells with migratory and tissue remodelling
capacities. However, microscopic views of explants at late stages of
in vitro culture disclosed a virtually complete lack of cells within
the remaining structures.
Slight methodological changes to the protocol allowed for the
establishment of a permanent cell line, which was subsequently
adapted to standard culture media and could be used in vitro and in
vivo in mouse models. Again, these cells pheno-copy the primary
tumour of origin closely and generate tumours in immunocom-
promised mice, which are indistinguishable from primary cancers,
and thus provide valuable sources for tumour cell studies.
In summary, we present a rapid and facile method for the
retrieval of vital tumour cells from primary carcinoma biopsies,
which are of great use for the further study in vitro or in vivo in
animal models. With this method, multiple testing and/or
reproduction of experiments with primary tumours is feasible in
short time, without a need for additional, costly devices, and
without the influence of enzymatic treatment.
Supporting Information
Figure S1 In vitro characterisation of explants. (A) Single
cells migrate out in vitro through incision in explants. (B) Overview
of the structure of explants in vitro at day 0, 2, and 3. Explants were
stained for the expression of EpCAM at the indicated time points.
The structure of explants disintegrates over time, releasing
EpCAM-positive cells from the united cell structure. (C) Single
cells, which have migrated out of explants in vitro, strongly express
cytokeratins and lack the fibroblast marker 5B5. Shown are
representative examples.
(TIFF)
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